Pip Marks

921 total citations
14 papers, 291 citations indexed

About

Pip Marks is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Pip Marks has authored 14 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 11 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in Pip Marks's work include Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). Pip Marks is often cited by papers focused on Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). Pip Marks collaborates with scholars based in Australia, United States and Thailand. Pip Marks's co-authors include Gregory J. Dore, Gail Matthews, Sharon R. Lewin, Stephen Locarnini, Scott Bowden, Joe Sasadeusz, Anchalee Avihingsanon, Kiat Ruxrungtham, David A. Cooper and Janaki Amin and has published in prestigious journals such as Hepatology, Journal of Virology and Journal of Hepatology.

In The Last Decade

Pip Marks

13 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pip Marks Australia	8	273	249	91	26	10	14	291
Motswedi Anderson Botswana	9	213 0.8×	176 0.7×	86 0.9×	25 1.0×	4 0.4×	37	235
Yi‐Chia Huang Taiwan	11	178 0.7×	161 0.6×	164 1.8×	77 3.0×	11 1.1×	20	301
Simnikiwe H. Mayaphi South Africa	9	148 0.5×	95 0.4×	93 1.0×	52 2.0×	6 0.6×	17	204
Ida Sperle Germany	9	300 1.1×	278 1.1×	75 0.8×	20 0.8×	3 0.3×	16	344
Murad Ruf United Kingdom	10	260 1.0×	262 1.1×	159 1.7×	26 1.0×	28 2.8×	21	329
A. D’Arminio Monforte Italy	7	149 0.5×	115 0.5×	96 1.1×	36 1.4×	42 4.2×	18	230
R Piscopo Italy	5	187 0.7×	147 0.6×	133 1.5×	78 3.0×	26 2.6×	10	287
T.E.M.S. de Vries-Sluijs Netherlands	8	289 1.1×	244 1.0×	162 1.8×	96 3.7×	19 1.9×	13	382
Thomas Huleux France	10	101 0.4×	95 0.4×	116 1.3×	50 1.9×	23 2.3×	18	193
Shauna Onofrey United States	4	115 0.4×	92 0.4×	56 0.6×	10 0.4×	11 1.1×	7	153

Countries citing papers authored by Pip Marks

Since Specialization

Citations

This map shows the geographic impact of Pip Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pip Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pip Marks more than expected).

Fields of papers citing papers by Pip Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pip Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pip Marks. The network helps show where Pip Marks may publish in the future.

Co-authorship network of co-authors of Pip Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Pip Marks. A scholar is included among the top collaborators of Pip Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pip Marks. Pip Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Dore, Gregory J., Behzad Hajarizadeh, Jason Grebely, et al.. (2020). Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study. Journal of Hepatology. 73. S127–S127. 2 indexed citations

Hajarizadeh, Behzad, Jason Grebely, Marianne Byrne, et al.. (2020). Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study. SSRN Electronic Journal.

Martinello, Marianne, Jasmine Yee, Sofia Bartlett, et al.. (2019). SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia. Journal of Hepatology. 70(1). e734–e734. 1 indexed citations

Martinello, Marianne, Chloe Orkin, Graham Cooke, et al.. (2019). THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. Journal of Hepatology. 70(1). e231–e231. 3 indexed citations

Dore, Gregory J., Jordan J. Feld, Alexander Thompson, et al.. (2019). PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. Journal of Hepatology. 70(1). e110–e110. 2 indexed citations

Lamoury, F., Behzad Hajarizadeh, Evan B. Cunningham, et al.. (2017). Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology. 92. 32–38. 24 indexed citations

Baker, David, Maryam Alavi, Richard Hallinan, et al.. (2014). Delivery of treatment for hepatitis C virus infection in the primary care setting. European Journal of Gastroenterology & Hepatology. 26(9). 1003–1009. 12 indexed citations

Avihingsanon, Anchalee, Joe Sasadeusz, Jennifer Audsley, et al.. (2013). CXCL-10, Interleukin-12 and Interleukin-21 are not Immunological Predictors of Hbeag Seroconversion in HIV-1–HBV Coinfection following HBV-Active Antiretroviral Therapy. Antiviral Therapy. 19(4). 429–433. 4 indexed citations

Avihingsanon, Anchalee, Gail Matthews, Sharon R. Lewin, et al.. (2012). Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. AIDS Research and Therapy. 9(1). 6–6. 25 indexed citations

10.

Matthews, Gail, Eric C. Seaberg, Gregory J. Dore, et al.. (2009). Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 23(13). 1707–1715. 42 indexed citations

11.

Chang, Judy, Sunee Sirivichayakul, Anchalee Avihingsanon, et al.. (2009). Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. Journal of Virology. 83(15). 7649–7658. 35 indexed citations

12.

Lewin, Sharon R., Ruy M. Ribeiro, Anchalee Avihingsanon, et al.. (2008). Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy #. Hepatology. 49(4). 1113–1121. 18 indexed citations

13.

Matthews, Gail, Anchalee Avihingsanon, Sharon R. Lewin, et al.. (2008). A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†. Hepatology. 48(4). 1062–1069. 102 indexed citations

14.

McGregor, James, et al.. (2003). Factors influencing hepatitis B vaccine uptake in injecting drug users. Journal of Public Health. 25(2). 165–170. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact